DB06129InvestigationalGene Therapies
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in mice.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified) and lung cancer.Curator reviewed
- Code names
- SVV-001
What you can answer from here — as of April 02, 2025
Which companies are running trials of SVV-001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account